# Phase III Clinical Study of Recombinant Erythropoiesis Stimulating Protein Injection (rESP) in the Treatment of Anemia in Hemodialysis Patients With Chronic Renal Failure

Study · id `cardio:ct-nct05211167` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05211167](<https://clinicaltrials.gov/study/NCT05211167>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05211167

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 300 participants.

## Technical summary

Registry record NCT05211167. Randomized; no masking; primary purpose treatment. Start 2021-07-01 (actual); primary completion 2023-06-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 300 participants (planned count; ClinicalTrials.gov record NCT05211167, source copy `cardio:ctgov-nct05211167-2022-01-27`, retrieved 2026-10-26)
- Started: 2021-07-01 (actual) (ClinicalTrials.gov record NCT05211167, source copy `cardio:ctgov-nct05211167-2022-01-27`, retrieved 2026-10-26)
- Primary completion: 2023-06-30 (anticipated) (ClinicalTrials.gov record NCT05211167, source copy `cardio:ctgov-nct05211167-2022-01-27`, retrieved 2026-10-26)
- Completion: 2023-12-30 (anticipated) (ClinicalTrials.gov record NCT05211167, source copy `cardio:ctgov-nct05211167-2022-01-27`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05211167, source copy `cardio:ctgov-nct05211167-2022-01-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05211167-2022-01-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: Phase III Clinical Study of Recombinant Erythropoiesis Stimulating Protein Injection (rESP) in the Treatment of Anemia in Hemodialysis Patients With Chronic Renal Failure
- Condition: Kidney Failure, Chronic
- Condition: Hemodialysis
- Intervention (Drug): Human Erythropoiesis Injection (CHO cell)
- Intervention (Drug): Recombinant Erythropoiesis Stimulating Protein Injection(CHO cell)
- Lead sponsor: Shenyang Sunshine Pharmaceutical Co., LTD.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)

## Provenance

Content hash: 3a129d645237904d428104a3ac048954b7043a3ddbaf7f6d2b26bc6e81039fcc
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
